Q-omics provides the consensus-scored PDE6G profile across patient tissues and cancer cell-line models. PDE6G expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PDE6G is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PDE6G RNA expression shows 14,654 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where PDE6G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE6G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE6G survival associations across molecular data types. PDE6G RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE6G RNA expression–survival associations across cancer types. High PDE6G expression shows unfavorable associations in LGG and GBM, but favorable associations in UVM, HNSC, SCLC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PDE6G RNA expression.
This table summarizes PDE6G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PDE6G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE6G shows lower tumor expression in KIRC, KICH, COAD and LUSC and higher tumor expression in HNSC and BRCA. The KIRC box plot shows higher PDE6G RNA expression in normal versus tumor tissue (log2 FC = −0.952, t-test p < 0.001).
This table shows molecular features associated with PDE6G in patient tissues and cancer cell lines. In patient samples, PDE6G shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE6G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
